Business Wire

LEAPMOTOR

25.4.2022 09:02:07 CEST | Business Wire | Press release

Share
Leapmotor's First Mass Production Model With CTC Technology

On February 25, 2022, Leapmotor for the first time announced the highlights of its new model C01. It is an electric mid-to-large-sized sedan developed on its C-Vehicle Platform, and also the first mass production model equipped with CTC battery technology, acceleration to 100 km/h in less than 4 seconds, 5-meter plus length and 700km ultra-long range. It will also further expand the portfolio with a planned launch in Q2 of 2022.

Technological and Natural Aesthetics to Create an Inner "Style"

Leapmotor C01 takes natural aesthetics as the design concept, emphasizing smart mobility experience. The design of C01 is featured with technical elements, offering a comfortable environment while the immersive cabin brings a luxurious experience for young, high-end, urban families.

C01 Key Product Features Unveiled

Because of Leapmotor's full-suite of R&D capabilities, the C01 offers compelling features – CTC technology, acceleration, vehicle length and NEDC range. It is set to become a popular product on the EV market.

NO.1 – Leapmotor’s First Mass Production Model with CTC Technology

CTC (Cell-To-Chassis) is a cutting-edge technology that integrates battery into the chassis, leading to greater shock resistance and improved strength of the vehicle. The C01 offers better handling performance, range and collision safety thanks to the CTC Technology.

0-100 km/h Acceleration in less than 4 seconds — Fastest acceleration among electric sedans within the same class in China, supercar-level performance

Leapmotor C01 has one of the fastest acceleration among electric sedans within the same class in China. It is equipped with "Higher Dimension" intelligent power system, using variable-structured oil-cooled electric drive with up to 1 million kilometers lifespan and the world's top NVH performance and power efficiency, meeting the demand for long range and high performance of EVs. In addition, flush door handle, sportback design, 0.226 ultra-low drag coefficient and 5% reduced vehicle weight will offer better performance.

Vehicle Length of over 5 Meter — Mid-to-large-sized sedan

As a mid-to-large sedan, Leapmotor C01 has a 5-meter plus length, wider rear legroom and large trunk space, offering exceptional comfort.

700km Ultra-long NEDC Range — Meeting long-distance travel needs

The C01 is equipped with a 90kWh ultra-large battery, capable of 700km ultra-long NEDC range, meeting consumer needs for long-distance travel. With penetrated large module scheme and intelligent battery management system can improve battery life, range and overall safety.

Full-suite of R&D capabilities Empowering Innovation

Leapmotor has been committed to growing its portfolio of R&D capabilities, obtaining and declaring 1,474 patents, 939 of which have been approved, and more than 40% of which are innovation patents.

Leapmotor increased its product line in 2021 by releasing the C11 as a mid-sized smart electric SUV, entering the RMB 150,000-200,000 SUV sector that has long been dominated by automakers.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar

ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release

First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno

BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release

Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures

IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release

IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye